Pfizer pregabalin NDA
Executive Summary
Pfizer will submit pregabalin NDA in the U.S. following March 2003 European submission, company says Sept. 6. Filing will include FDA-requested toxicological mechanistic studies. Pfizer had hoped to submit the application in 2002. The delay is the second for the Neurontin follow-on; the NDA was delayed in late 2001 while Pfizer added carcinogenicity data and studies supporting a generalized anxiety disorder indication (1"The Pink Sheet" Dec. 24, 2001, p. 18). Pfizer is seeking approval for add-on epilepsy, neuropathic pain and GAD...
You may also be interested in...
Pfizer Pregabalin NDA Will Include Anxiety Use; Filing Date Pushed To 2002
Pfizer's updated pregabalin NDA filing schedule calls for three initial indications - add-on epilepsy, neuropathic pain and generalized anxiety disorder - to be submitted in 2002
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.